Advocard (Magladen, Molsidomine, Folic Acid) tablets №30

Description

Composition

active ingredients: 1 tablet contains: magladene in the listing for 100% substance with a content of the sum of adenine nucleotides 18.6 – 29.25 mg, molsidomine in the listing for 100% substance – 0.3 mg, folic acid in the listing for 100% of the substance 0 .45 mg;

excipients: lactose, monohydrate; powdered sugar; silicon dioxide colloidal anhydrous; microcrystalline cellulose.

Pharmacodynamics.

ADVOCARD® is an original combined drug. It has anti-anginal and anti-ischemic effects, has membrane-protective and antioxidant effects, improves myocardial metabolism, protecting cells from hypoxia, and has an anti-atherosclerotic effect due to the normalization of homocysteine metabolism. The mechanism of action of ADVOCARD® is associated with the complex effect of the ingredients of the drug.

Magladen affects purine (adenosine) receptors and thus leads to the activation of potassium channels. Activation of potassium channels leads to inhibition of the entry of calcium ions in the cell, which is accompanied by anti-ischemic, membrane-stabilizing action, antiarrhythmic effect. By acting on ATP-dependent potassium channels (KATP) of mitochondria, magladen promotes the development of processes aimed at protecting the myocardium from damage associated with its ischemia. Due to the effect on purine receptors, Magladen has an antiplatelet effect.

Molsidomin and its active metabolites SIN 1 and SIN 1A are nitric oxide donors. Nitric oxide stimulates the guanylate cyclase system and activates ATP-sensitive potassium channels, which leads to blocking the entry of calcium ions into vascular cells and is accompanied by their expansion. This explains the synergistic effect of magladen and molsidomine on the effect on hemodynamic parameters. Unlike organic nitrates, the drug does not develop addiction. Molsidomin has a positive effect on systemic hemodynamics, reducing the load on the myocardium. By blocking the synthesis of platelet phospholipases and activating the synthesis of prostacyclin by the vascular wall, molsidomine exhibits antiplatelet properties.

Folic acid is involved in many metabolic processes. Particularly important is the participation of folic acid in the transformation of homocysteine, which is a factor in the development of atherosclerosis. By reducing the level of homocysteine, folic acid has an anti-atherosclerotic effect. By stimulating metabolic processes in the myocardium, folic acid improves its functional activity.

The drug in conditions of coronary insufficiency shows an energy-saving effect by reducing myocardial oxygen demand. ADVOCARD® reduces the amount of lactate in the myocardium, inhibits the activity of membrane-bound phospholipases, prevents structural and functional damage to cardiomyocyte membranes, and ensures the constancy of the quantitative and qualitative composition of membrane lipids. ADVOCARD® improves coronary blood flow, increases exercise tolerance, reduces the frequency and severity of angina attacks. In patients with heart failure, improving the metabolic supply of the myocardium and the normalization of hemodynamic parameters increases the ejection fraction of the left ventricle. The use of the drug helps to normalize the concentration of magnesium ions in tissues. ADVOCARD® exhibits an antiarrhythmic effect.

Indications

As part of the complex therapy of coronary heart disease and heart failure, angina pectoris and rest; prevention and treatment of angina attacks.

Contraindications

• Individual hypersensitivity to the drug or its ingredients.
• Severe arterial hypotension; severe forms of bronchial asthma;
• cardiogenic and other types of shock;
• acute stage of myocardial infarction, especially with low blood pressure; traumatic brain injury;
• sinoatrial and atrioventricular block II-III degree;
• hemorrhagic stroke;
• glaucoma, especially angle-closure; inaccurate malignant neoplasms;
• children;
• period of pregnancy or lactation.